Concert Pharmaceuticals

Concert Pharmaceuticals, Inc. was founded in April 2006 as a clinical-stage biotechnology company dedicated to creating new drugs through a novel scientific approach utilizing the natural element deuterium. The company’s approach starts with previously studied compounds, including approved drugs, where deuterium substitution has the potential to enhance clinical safety, tolerability, or efficacy. Concert's innovative drug pipeline targets autoimmune diseases and central nervous system (CNS) disorders.